What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Amgen Inc.'s unaudited financial results for the three and twelve months ended December 31, 2011, and its financial position as of December 31, 2011. It also details the non-GAAP financial measures used by the company and provides reconciliations to GAAP.

What types of adjustments does Amgen make to its GAAP results for non-GAAP reporting?

Amgen makes various adjustments to its GAAP results, including but not limited to: the impact of expensing stock options, expenses related to business combinations and divestitures (like the BI Fremont transaction and BioVex acquisition), amortization of acquired R&D technology and product rights, cost-saving initiative expenses (including severance), contingent consideration adjustments, legal expenses, non-cash interest expense on convertible notes, and the tax effects of these adjustments. For 2010, adjustments also included asset impairment charges and certain tax benefits.

Why does Amgen present non-GAAP financial measures?

Amgen believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. Management uses these measures for internal budgeting and financial planning, and they are intended to offer a clearer view of operational performance by excluding items that may be non-recurring or non-cash in nature, thereby facilitating comparisons between reporting periods.

Are the non-GAAP measures presented in this filing a replacement for GAAP results?

No, Amgen explicitly states that these historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). They are intended to supplement, not replace, the standard GAAP financial reporting.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on January 26, 2012, to report its unaudited financial results for the fourth quarter and full year ended December 31, 2011, along with its financial position as of year-end. The filing primarily detailed the company's use of non-GAAP financial measures, providing reconciliations for these adjustments. Investors should note that Amgen management uses these non-GAAP measures to supplement GAAP results, believing they offer valuable insights for analysis and facilitate comparisons across reporting periods. The company outlined various adjustments made to GAAP figures, including those related to stock option expensing, transaction-specific expenses from acquisitions and divestitures (such as the Boehringer Ingelheim Fremont transaction and BioVex Group acquisition), amortization of intangible assets, cost-saving initiatives, legal proceedings, and non-cash interest expense on convertible notes. These adjustments aim to present a clearer picture of ongoing operational performance by excluding non-recurring or non-cash items. The report also highlighted a non-GAAP measure for total outstanding debt, excluding the impact of a new accounting standard on convertible notes.

Key Highlights

1Amgen announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011.
2The company provided detailed reconciliations of its non-GAAP financial measures to U.S. GAAP.
3Key non-GAAP adjustments for 2011 included stock option expensing, transaction-related expenses (e.g., BI Fremont, BioVex), R&D intangible asset amortization, cost-saving initiatives, and legal expenses.
4The filing disclosed non-GAAP adjustments for 2010, which included stock option expensing, R&D intangible asset amortization, asset impairment charges, and non-cash interest expense.
5Amgen highlighted a non-GAAP measure for total outstanding debt as of December 31, 2011, excluding the impact of a new accounting standard on convertible notes.
6The company indicated that these non-GAAP measures are used for internal budgeting and financial planning and are provided as supplementary information to investors.
7The report emphasizes that non-GAAP measures are not a substitute for GAAP financial statements but are intended to facilitate further analysis.

AMGEN INC 8-K Report, Financial Results (Jan 26, 2012)

Summary

Key Highlights

Frequently Asked Questions